Observational educational study assessing efficacy of training of physicians and hypertensive patients treated with Perindopril /Indapamide single pill combination to improve antihypertensive efficacy and treatment compliance

Submission date	Recruitment status No longer recruiting	Prospectively registered		
25/09/2019		☐ Protocol		
Registration date 18/11/2019	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited 03/02/2020	Condition category	[] Individual participant data		

Plain English summary of protocol

Background and study aims

In clinical practice, doctors may struggle to get their patients' blood pressure controlled, and patients might not follow their recommended treatment.

The aim of this study is to assess if training of the physicians and patients with essential hypertension and use of the single-pill combination of the blood pressure controlling drugs perindopril/indapamide may improve hypertensive efficacy of treatment and treatment compliance.

Who can participate?
Patients with essential hypertension

What does the study involve?

This study collects data from patients treated with the drug perindopril arginine 10 mg /indapamide 2.5 mg (alone or in addition to other antihypertensive drugs), according to their doctor's decision. Patients are assigned into one of the three groups. In group 1, patients are followed-up by the physician according to routine clinical practice; in group 2, physicians receive training; in group 3, physicians receive training and patients are trained in self-monitoring of BP. All patients received the treatment with single pill combination perindopril/indapamide.

What are the possible benefits and risks of participating?

In this study the decision about an administration of single pill combination perindopril /indapamide was made by the physician in accordance with clinical practice. Therefore, any potential drug-related benefit or risk is linked to label for this drug.

Where is the study run from?

Department of Preventive and Emergency Cardiology, Sechenov First Moscow State Medical University

When is the study starting and how long is it expected to run for? November 2014 to April 2016

Who is funding the study? Servier Pharmaceuticals

Who is the main contact? Prof. Maria Glezer 287ast@mail.ru

Contact information

Type(s)

Scientific

Contact name

Prof Maria Glezer

ORCID ID

http://orcid.org/0000-0002-0995-1924

Contact details

Department of Preventive and Emergency Cardiology, Sechenov First Moscow State Medical University. 2-4 Bolshaya Pirogovskaya st.

Moscow Russian Federation 119991 +7(985)7630420 rektorat@sechenov.ru

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

IC4-06597-011-RUS

Study information

Scientific Title

Non-interventional educational multicenter open-label study to assess efficacy of training of the physicians and patients with essential hypertension receiving Perindopril/Indapamide single-pill combination to achieve the target levels of blood pressure and to increase the treatment compliance

Acronym

FORSAGE

Study objectives

Physician and patient training and use of single-pill combination of perindopril/indapamide may improve antihypertensive efficacy and treatment compliance

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 20/06/2014, Interuniversity Ethical Committee (119002, 37, bld. 2, Gagarinsky Lane, Moscow, tel. +7 (916) 2607664), ref: 06-14

Study design

Non-interventional educational multicenter open-label study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

GP practice

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Arterial hypertension

Interventions

This study collects data from patients treated with the drug perindopril arginine 10 mg /indapamide 2.5 mg (alone or in addition to other antihypertensive drugs), according to their doctor's decision.

Patients are assigned into one of the three groups. In group 1, patients are followed-up by the physician according to routine clinical practice; in group 2, physicians receive training; in group 3, physicians receive training and patients are trained in self-monitoring of blood pressure.

Patient blood pressure, as well as safety, is evaluated at baseline, then 2 weeks, 1 and 3 months after starting treatment with perindopril/indapamide single pill combination. Questionnaires are administered at baseline and end of the study.

The physician training includes the detailed consulting of the patient in problems of arterial hypertension (AH), providing of printed matter regarding the problem of AH, blood pressure (BP) control, diet in patients with AH, physical load, quitting smoking.

Intervention Type

Other

Primary outcome measure

Blood pressure (mmHg) at baseline and 3-months

Secondary outcome measures

- 1. Achievement of target levels of BP
- 2. Treatment compliance
- 3. Adverse Event/Adverse Reaction

Overall study start date

12/04/2014

Completion date

18/04/2016

Eligibility

Key inclusion criteria

- 1. Adult patients (≥18 years)
- 2. Essential hypertension
- 3. BP > 150 /90 mmHg at the background of the current therapy
- 4. Physician's decision to administer Perindopril/Indapamide Single-Pill Combination due to inefficacy of the previous monotherapy or combination therapy and according to the indications 5. Patient's consent to participate in the study

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

2000

Total final enrolment

1969

Key exclusion criteria

- 1. Secondary hypertension
- 2. Pregnancy, breast-feeding
- 3. Severe cardiovascular disease (acute myocardial infarction or acute cerebrovascular accident within the last 6 months)
- 4. Diabetes mellitus in the stage of decompensation
- 5. Severe hepatic impairment
- 6. Renal transplantation
- 7. Nephrectomy or the presence of a single kidney
- 8. Hypokalemia or hyperkalemia
- 9. Chronic alcoholism, abuse of drugs
- 10. Contraindications for taking indapamide/perindopril arginine 2.5 mg/10mg or individual components
- 11. History of ACEi/indapamide/sulfonamide intolerance
- 12. Systemic connective tissue diseases
- 13. Aortic stenosis
- 14. Malignant neoplasm
- 15. Hypersensitivity reactions of any etiology
- 16. Presence of indapamide 1.25 mg/perindopril 5 mg or indapamide 2.5 mg/perindopril 10 mg or free combination of its compounds (perindopril/indapamide) in a current therapy

Date of first enrolment

01/11/2014

Date of final enrolment

28/02/2015

Locations

Countries of recruitment

Russian Federation

Study participating centre

Department of Preventive and Emergency Cardiology, Sechenov First Moscow State Medical University

2-4 Bolshaya Pirogovskaya str. Moscow Russian Federation 119991

Sponsor information

JBC 'Servier'

Sponsor details

bld.7, Lesnaja str. Moscow Russian Federation 125196 +7(495) 937-0700 natalya.logunova@servier.com

Sponsor type

Industry

ROR

https://ror.org/034e7c066

Funder(s)

Funder type

Industry

Funder Name

Servier

Alternative Name(s)

Servier Laboratories, Laboratoires Servier

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

France

Results and Publications

Publication and dissemination plan

We are planning the publication in the journal Cardiology and Therapy.

Intention to publish date

31/03/2020

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a non-publically available repository

IPD sharing plan summary

Stored in repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2016	26/09/2019	Yes	No
Results article	results	01/06/2020	03/02/2020	Yes	No